(R)-(+)-Thalidomide

Also known as: (+)-Thalidomide, (R)-Thalidomide, (R)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, (R)-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, NSC 91729, 1H-Isoindole-1,3(2H)-dione, 2-[(3R)-2,6-dioxo-3-piperidinyl]-

(R)-(+)-Thalidomide (CAS 2614-06-4) is a compound in the Organic Bases category listed in the Jingsj chemical database. It has the molecular formula C13H10N2O4 and a molecular weight of 258.22900 g/mol. Key properties include a melting point of 269-271ºC, a boiling point of 509.7ºC at 760 mmHg, a density of 1.503g/cm3 and a flash point of 262.1ºC. It is classified under GHS with signal word Danger and hazard statements H302 — Harmful if swallowed and H360 — May damage fertility or the unborn child. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 2614-06-4
Jingsj CID: J-34673-3
Molecular Formula: C₁₃H₁₀N₂O₄
Molecular Weight: 258.22900 g/mol
Category: Organic Bases
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Melting Point	269-271ºC
Boiling Point	509.7ºC at 760 mmHg
Density	1.503g/cm3
Flash Point	262.1ºC
Exact Mass	258.06400
PSA	83.55000
LogP	0.35450
Vapor Pressure	1.65E-10mmHg at 25°C
Refractive Index	1.646
Storage Conditions	-20°C

GHS Safety & Compliance

Irritant / Health HazardSignal word: Danger

H302 — Harmful if swallowed
H360 — May damage fertility or the unborn child

Activity & Biological Data

Additional Information	[1]. Murphy S, et al. Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. J Pharm Pharmacol. 2007 Jan;59(1):105-14. [2]. Eriksson T, et al. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol. 2000 Jul;52(7):807-17.

Additional Information

[1]. Murphy S, et al. Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. J Pharm Pharmacol. 2007 Jan;59(1):105-14. [2]. Eriksson T, et al. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol. 2000 Jul;52(7):807-17.

Customs & Trade Information

HS Code	2925190090
Summary	2925190090 other imides and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0%

Frequently Asked Questions

What is the CAS number of (R)-(+)-Thalidomide?

The CAS number of (R)-(+)-Thalidomide is 2614-06-4.

What are the molecular formula and molecular weight of (R)-(+)-Thalidomide?

(R)-(+)-Thalidomide has molecular formula C13H10N2O4 and molecular weight 258.22900 g/mol.

Is (R)-(+)-Thalidomide hazardous?

(R)-(+)-Thalidomide has GHS signal word Danger and hazard statements H302 — Harmful if swallowed; H360 — May damage fertility or the unborn child.

What are the upstream and downstream products of (R)-(+)-Thalidomide?

For (R)-(+)-Thalidomide, Upstream Products: Thalidomide, N-Carbethoxyphthalimide, Phthalic anhydride; Downstream Products: (S)-Thalidomide.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "(R)-(+)-Thalidomide (CAS 2614-06-4)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-34673-3 (accessed 2026-11-07).

Data for reference only; verify product details with suppliers before purchase.